This study is a prospective, observational 8-year follow-up of 300 stable unselected coronary artery disease patients entering elective coronary angiography in 2002 -03. Recorded were clinical outcomes, health-related quality of life (HRQoL), and secondary care costs after coronary artery bypass graft (CABG) surgery, percutaneous coronary intervention (PCI), or medical therapy (MT).
Introduction
Economic evaluation of healthcare for operational planning and decision-making is vital for allocation of resources to effective treatments that provide patients the greatest possible health benefits at reasonable costs. 1 Clinical studies based on patients' selfassessments as an outcome measure of treatment effectiveness are essential for cost-effective secondary healthcare. 2 Measurement of patients' perceived health-related quality of life (HRQoL) with a standard generic HRQoL instrument, such as the 15D, provides a patient-reported outcome (PRO) reflecting a clinical intervention's effect on health and well-being. 3 Management strategies for coronary artery disease (CAD) include medical therapy (MT) and myocardial revascularization by coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). Their utilization in individual patients depends on the symptoms and the angiographic coronary lesion complexity. Treatment of CAD aims not only to decrease mortality and morbidity but also to improve quality of life. Consequently, there is a growing interest in health gains of treatment assessed by PROs such as HRQoL. 4 Some earlier studies suggest that both revascularization procedures are associated with greater angina symptom relief and improve HRQoL more than MT. 5 -7 On the other hand, the addition of PCI to MT compared with MT alone has not been proven superior in reducing mortality and major cardiovascular events. 8 In randomized trials, HRQoL improved to a greater extent at 6 and 12 months after CABG than after PCI, 9,10 but in chronic stable angina, the difference tended to disappear after 3 years. 11 The degree of HRQoL improvement is associated with relief of angina. 9, 12 A non-randomized study suggested that HRQoL improved until 6 months after both CABG and PCI, yet deteriorated towards the end of the 3-year follow-up. 13 CABG is the standard procedure for significant left main coronary artery (LMCA) stenosis or three-vessel disease. Randomized trials demonstrate that CABG reduces the need for repeat revascularization procedures 14 and is beneficial in diabetic patients. 15, 16 In patients with diabetes and multi-vessel CAD, health gain assessed by PRO in extended follow-up beyond 2 years was similar for both CABG and PCI. 17 Costs emerging from CABG are almost double of those from PCI, although in three-vessel disease the cost difference becomes narrower during follow-up. 18 In a 12-month follow-up, CABG proved clinically beneficial and cost-effective, whereas the clinical benefit of PCI failed to justify its cost. 19 Furthermore, a long-term follow-up of 10 years found CABG to be cost-effective compared with PCI. 20 In a recent large observational cost-effectiveness study, CABG had better outcome and higher cost than PCI in stable multi-vessel CAD. 21 Both clinical benefit and cost-effectiveness need to be proven for the alternative management strategies of CAD to guarantee sensible allocation of resources. Studies assessing long-term health outcomes in stable CAD under the routine care of a secondary care hospital are few. Our study elucidates long-term health outcomes and costs of CAD treatment from the point of view of a secondary care provider.
Methods

Patient recruitment
Consecutive stable patients entering elective coronary angiography due to suspected CAD at the Department of Cardiology of the Helsinki University Central Hospital (HUCH) between November 2002 and March 2003 were asked to fill in the 15D HRQoL questionnaire at baseline prior to the diagnostic workup, and 6 months, and 8 years after start of treatment. A total of 350 patients responded to the baseline questionnaire (response rate 68%). Of 350 patients, who returned the 15D questionnaire, 300 patients with CAD were included in the final study group. The diagnosis of CAD was based on prior myocardial infarction (MI), findings consistent with CAD in a prior coronary angiography, or coronary angiography findings at study baseline. The exclusion of 50 patients was based on lacking history of CAD or lacking objective CAD findings in baseline coronary angiography (n ¼ 43), or concurrent valvular disease in patients who underwent valvular replacement in addition to CABG during the same surgery (n ¼ 7).
Patient characteristics at baseline, data on repeat revascularization procedures, rehospitalization, treatment complications, and clinical outcomes during long-term follow-up were obtained from HUCH patient records. Mortality data were obtained from the Causes of Death register, Statistics Finland.
Health-related quality of life
HRQoL was measured by the 15D (version 2), a standardized, generic HRQoL instrument that provides a HRQoL profile and a single index score. The questionnaire is self-administered by the patient and consists of 15 dimensions of health: mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, anxiety, vitality, and sexual activity. Each dimension has five levels. The single index score (15D score), representing the overall HRQoL, and the dimension level values, reflecting the goodness of the levels relative to no problems on the dimension, both on a 0 -1 scale, are calculated from the health state descriptive system by using a set of population-based preference or utility weights. 22 The minimal clinically important change in the 15D score has been estimated at 0.015 for improvement and 20.015 for deterioration. 23 In most of important properties, the 15D has been shown to be equally good or superior to other preference-based generic HRQoL instruments. 24 HRQoL data of the general population covering a representative sample of the Finnish population aged ≥30 years was obtained from the National Health 2000 Health Examination Survey. 25 The population sample was weighted to reflect the age and gender distribution of patients.
Cost data and the use of secondary healthcare services
Data concerning costs and utilization of secondary care services during the years 2002 -11 for 296 patients living in the immediate catchment area of the hospital were obtained from the administrative database of the hospital. The cost data covered all costs related to the field of cardiology during the study period (intervention, ward, ambulatory visits, laboratory, radiology, pathology) and included both pre-and postintervention outpatient visits to the hospital. The cost analysis was carried out from a secondary healthcare provider perspective; therefore, no productivity costs or outpatient drug costs were included.
The costs are at current prices for each actual year without adjusting for inflation. The costs are presented as total costs during the 8-year follow-up. Currency used is euro (E).
Statistical analysis
SPSS statistical software version 22 (SPSS, Inc., Chicago, IL, USA) was used for statistical analyses. The results are given as mean (SD) or as percentages. For continuous variables, the significance of the differences between groups was analysed using one-way ANOVA. When comparing percentage distributions between the groups, x 2 test was used. The significance of the differences between before and after treatment scores was analysed with Student's paired samples t-test. A direct comparison of the 8-year mortality (or survival) or 8-year HRQoL scores of the surviving patients between the treatment groups is likely to be biased, as baseline patient characteristics differ significantly between the groups and these characteristics probably influence the choice of the treatment. This holds true for all efforts to study the real everyday effectiveness of unselected patients. Consequently, to facilitate a fair comparison, an adjustment for all relevant baseline characteristics available was applied.
A potential difference in the 8-year survival between the treatment groups was explored using the Cox regression with the number of days alive during the follow-up as the dependent variable and all relevant baseline characteristics available, including the 15D score, and treatment modes as explanatory variables. A survival curve adjusted for these variables was also produced.
A similar approach was used to explore whether there is a potential difference between the groups in the 8-year change in HRQoL (15D score) and costs among patients alive. The variance in these variables was explained by a linear regression model using the change in 15D score from baseline to 8 years and 8-year costs as the dependent variables and the same set of explanatory variables as described above. The threshold of statistical significance was set at ≤0.05. The group assignment of the patients is based on intention to treat.
Ethical considerations
All patients received routine treatment and were not, besides being asked to fill in the 15D questionnaires and to give a written informed consent, approached in other manners. The protocol for the initial 
Results
Patient characteristics
Baseline characteristics of the 300 patients by their treatment assignment are presented in Table 1 . The treatment groups differed statistically significantly regarding the following variables: mean age, prevalence of peripheral arterial disease, gender distribution, New York Heart Association classification, left ventricular ejection fraction, number of diseased vessels, and percentage of patients who had undergone a previous CABG or PCI.
Clinical outcomes
In patients assigned to MT alone, data on medication, obtained from hospital records, covered 94% (n ¼ 99) of the patients. MT was considered optimal if patients were prescribed an antiplatelet drug (acetylsalicylic acid or other antiplatelet), b-blocker, statin, and angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist. After baseline coronary angiography, 84% of MT group patients were prescribed antiplatelet drugs, 94% b-blockers, 81% statins, and 45% angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist. Only onequarter were prescribed the above-mentioned optimal MT combination. Prolonged action nitrates were prescribed to 59% and calcium antagonists to 31%. Additionally, 8% received an anticoagulation therapy prescription. The need for revascularization during follow-up was higher in the PCI group (23.4%) than in the MT (5.7%) or CABG (3.0%) groups. Seven (6.9%) patients who initially underwent CABG were during follow-up referred to repeat coronary angiography, but only three (3.0%) needed revascularization by PCI. Twenty (21.3%) patients assigned to PCI at baseline were treated by repeat PCI once during long-term follow-up and three (3.2%) patients twice, while two (2.1%) patients later underwent CABG. Six (5.7%) patients initially assigned to MT later required revascularization (PCI n ¼ 4, CABG n ¼ 2). Crossover between groups occurred overall in 18 (6.0%) cases from MT to revascularization, or between revascularization groups.
Cerebral stroke was diagnosed within 30 days after CABG in one patient. No additional patients suffered a stroke within 1 year from receiving treatment. During the 8-year follow-up, four patients who initially underwent CABG suffered a stroke, while in the MT group a stroke occurred in three patients and in the PCI group in one patient, respectively. All three patients requiring dialysis or treatment for nephropathy after baseline coronary angiography had a previous medical history of nephropathy. A permanent pacemaker was implanted to one patient due to third-degree atrioventricular block after PCI. Two patients who underwent CABG had excessive haemorrhage, the other required immediate reoperation. Pericardial tamponade led to resternotomy in three CABG patients, three patients developed mediastinitis after cardiac surgery, and two required post-operative dialysis. One patient required a permanent pacemaker due to third-degree atrioventricular block after CABG.
Mortality and health-related quality of life without adjustment for baseline characteristics Fifty-two (17.3%) patients died of any cause [CABG: n ¼ 19 (18.8%); PCI: n ¼ 15 (16.0%); MT: n ¼ 18 (17.1%)] during the 8-year followup, but there were no statistically significant differences between the groups regarding the number of all-cause deaths. Twenty-one (7%) patients died of CAD or MI during the 8-year follow-up and the groups did not differ statistically significantly regarding CAD mortality. Two of them died of MI during CABG. One patient assigned to MT died within the first year of follow-up. Overall, during the 8-year follow-up, MI occurred in 16 (5.3%) patients and was somewhat more prevalent in the CABG group (n ¼ 8, 7.7%) than in the PCI (n ¼ 4, 4.3%) or MT (n ¼ 4, 3.8%) groups.
At baseline, the 15D score was available from 295 patients and missing from 5 patients due to incomplete response to the 15D questionnaire. At 8 years, the 15D score was available from 206 patients and missing due to non-response from 42 patients still alive. There was no statistically significant difference between the respondents and non-respondents in any of the baseline characteristics.
At 6 months after entering treatment, CABG and PCI patients reported significant improvement on the following dimensions: mobility, breathing, and vitality. In addition, PCI patients reported significant improvement on the dimensions of distress, depression, and usual activities, and CABG patients on the dimensions of discomfort and symptoms and sexual activity. In long-term follow-up, both the PCI and CABG patients reported significant improvement on the dimension of breathing compared with baseline. PCI patients also reported significant improvement on the dimensions of distress and sleep (Figure 1) .
The mean baseline HRQoL score did not differ significantly between the treatment groups, but was in each group significantly lower than in the age-and gender-standardized sample of general population. At the 6-month follow-up, the mean (SD) HRQoL had improved in a significant manner in the CABG [from 0.828 
Survival and health-related quality of life with adjustment for baseline characteristics
The baseline characteristics contributed to the Cox survival model in a significant manner (P ¼ 0.001). When adjusted for these characteristics and with MT as the comparator, no statistically significant differences were found in the 8-year survival between CABG and MT or PCI and MT ( Table 2) . A model with CABG as the comparator showed that there was no statistically significant difference between PCI and CABG, either (B ¼ 0.477, P ¼ 0.342, odds ratio ¼ 1.611, 95% CI for odds ratio 0.603-4.307) (Figure 3) .
The same conclusion applies to the 8-year change in the 15D score: when standardized for the baseline characteristics and with MT as the comparator, no statistically significant differences were found between CABG and MT or PCI and MT ( Table 3 ). The adjusted R 2 was relatively low (0.116, P ¼ 0.001). The difference between PCI and MT in favour of MT is clinically important, but far from being statistically significant. A model with CABG as the comparator showed that there was no statistically significant difference between PCI and CABG, either, although the difference in favour of CABG is clinically important (B ¼ 20.043, P ¼ 0.496, 95% CI for B 20.166 to 0.81) ( Table 3) .
Costs
Mean total secondary care costs during the 8-year study period were the highest in the CABG group followed by the PCI group and the MT group ( Table 4 ). The differences in treatment group means reduced slightly when standardized for the baseline characteristics (means 16 730, 6920, and 4580 for CABG, PCI, and MT, respectively). The differences, however, remained statistically significant (data not shown). During the 8-year follow-up, patients who underwent CABG required more inpatient days due to CAD (mean 15.6 days) than patients in the other two groups (PCI mean 4.8 days, MT mean 4.3 days). Complications after cardiac surgery, such as infected sternal wounds, mediastinitis, or reoperation due to pericardial tamponade, were associated with prolonged initial hospitalization (outlier maximum 94 days) and raised the upper range of secondary care costs in the CABG group.
Discussion
Randomized controlled studies performed under special circumstances include highly selected patients, whereas our study assessed clinical outcomes and HRQoL in unselected CAD patients under routine care. Thus, our results reflect the true everyday effectiveness of treatments. Furthermore, the estimation of the utility of treatment is based on a PRO, the 8-year follow-up period is exceptionally long, and the response rate to the follow-up questionnaires is high (86% of baseline respondents alive at 6 months, and 96% of baseline respondents alive at 8 years, respectively). Consequently, we feel that our results illustrate the typical course of illness in CAD patients. The use of a generic HRQoL instrument may help to identify patient groups that benefit the most from each treatment and enables comparison of HRQoL gain after treatment. Our study of routine care indicates that only one-quarter of patients in the MT group received guideline-recommended optimal MT at discharge from secondary care in 2002-03. One might argue that the main purpose of the secondary care consultation was the diagnostic workup of suspected CAD, not the optimization of medication as primary care physicians are in charge of the patients' medical management. Regardless, we find it alarming that such a high number of patients in the MT group left specialized care with suboptimal medication. Similar findings have been reported elsewhere, 26 and many patients fail to receive guideline-recommended therapies as adherence to guidelines varies in routine care compared with controlled trials. Optimizing MT in routine care before revascularization enables to identify patients who become asymptomatic with MT alone and may help to avoid costs of revascularization.
27
A recent cost-effectiveness study favoured CABG in three-vessel disease and LMCA disease, 28 and it has been suggested that revascularization therapies should be reserved for stable CAD with disabling symptoms despite of optimal MT. 29 In our study group, those with complex CAD, i.e. multi-vessel disease and LMCA, were most commonly treated by CABG, according to contemporary guidelines. In patients assigned to CABG and PCI, HRQoL improved during the 6-month follow-up, whereas the mean HRQoL score remained at the baseline level in the MT group. One explanation might be the suboptimal discharge medication of these patients. Unfortunately, data on medication at the 6-month follow-up were unavailable and, consequently, it is impossible to verify this hypothesis. In addition, several of the MT group patients had undergone invasive coronary procedures prior to baseline, and at this stage of CAD, there was little to be done to help them.
Real-world data have demonstrated a continued high risk for cardiovascular events in 1-year survivors of MI. 30 A higher rate of repeat revascularization after PCI has shown to be associated with reduced HRQoL. 17, 31 In agreement with previous findings, 14 the need for repeat revascularization was higher in the PCI group than in the other two groups, while patients treated by CABG seldom needed repeat revascularization. In the majority of the patients originally assigned to PCI, repeat revascularization was performed by PCI; only two were treated by CABG. A recent study reported a higher stroke rate after CABG compared with PCI. 32 Considering the relatively small volume of our data, firm conclusions about the incidence of stroke after CABG compared with other treatment modalities cannot be drawn, although four patients suffered a stroke in the CABG group during the 8-year follow-up compared with three in the MT group and only one in the PCI group. The groups did not significantly differ regarding cardiovascular death or overall mortality and it seems death was not prevented any better by invasive treatments than by MT alone. The conclusion of no statistically significant difference in the 8-year mortality remained regardless of adjustment for differences in the baseline characteristics.
Our results demonstrate that CABG and PCI resulted in a statistically significant and clinically important short-term improvement in HRQoL, as measured at 6-month follow-up. At 8 years from treatment start, the condition of CABG and PCI patients alive appeared rather good, as the statistically significant difference in the mean HRQoL observed at baseline between the patients and age-and gender-standardized general population was no longer present, whereas in the MT group it was. When the groups were adjusted for baseline characteristics, however, no statistically significant differences between treatment groups were found in the HRQoL at 8 years. This corroborates earlier findings that short-term HRQoL benefits from CABG and PCI tend to disappear in a longer period of time.
Although several of the patients in the MT and PCI groups required additional secondary care consultations and rehospitalization during the follow-up, the long-term mean secondary care costs in the CABG group were over two-fold than those in the PCI group and almost four-fold compared with those of the MT group. The differences remained by and large even after adjustment for baseline characteristics. The long-term costs of medication might possibly be higher in the MT group than in the other groups. Differences in medication cost, however, would probably even out as patients in PCI and CABG groups likewise receive MT post-intervention.
Limitations
The observed groups are based on the intention to treat at baseline. Due to the nature of this, long-term study of routine care crossover from one group to another occurred. As the treatment groups are not randomly assigned, adjustment for all relevant baseline characteristics available was applied. It is worth noting adjustment was possible only for observed confounding covariates and not for unobserved ones. Unobserved patient characteristics and preferences of patients and clinicians, together with possibly inadequately overlapping covariate distributions due to rather small group sizes, may be insufficiently adjusted for to allow credible comparisons of the groups. 33 The study included patients mainly from the same region, which may hamper the generalization of the results. Furthermore, the study size was fairly small and the study may have been underpowered to detect the statistical significance of small differences. Drug costs were not explored and may be particularly relevant in the MT group. Furthermore, primary care and productivity costs were not included in the analysis as it reflects mainly the cost of secondary healthcare.
Conclusions
Both CABG and PCI resulted in a statistically and clinically important short-term improvement of HRQoL. When adjusted for baseline characteristics, however, no statistically significant differences were found between the invasively or conservatively (MT) treated patient groups in 8-year all-cause mortality or HRQoL among survivors. The 8-year mean secondary care costs of CABG were over two-fold and almost four-fold, even after adjustment for baseline characteristics, compared with those of PCI and MT, respectively. Similar long-term follow-up studies assessing health outcomes in larger groups of stable CAD patients undergoing routine care are needed to corroborate the validity of these conclusions and to identify patients most likely to benefit from invasive treatment.
